Trials and Fibrillations with Dr John Mandrola

Should Mandatory Screening of Young Athletes End? John Mandrola reviews the most comprehensive study to date on cardiac screening of teenage athletes and sees the futility of searching for a deadly needle in a haystack.
Experts And Viewpoints, August 2018
Atrial Fibrillation: What's New? Not Much An investigation of AF trials on ClinicalTrials.gov found few studies of high scientific rigor. John Mandrola, MD, ponders the implications for patient management.
Experts And Viewpoints, August 2018
HRS 2018 Potential Major Problem With a Common Pacing Lead A poster presentation at HRS on lead failure with a popular St Jude Medical lead echoed a case familiar to John Mandrola, MD. He wasn't the only concerned EP calling for further investigation.
Experts And Viewpoints, May 2018
HRS 2018 CABANA: Initial Thoughts on AF Ablation vs Drugs The long-awaited trial was the star of HRS. The neutral primary endpoint sent some electrophysiologists into despair and others into spin mode, but Dr Mandrola sees value in the incremental move of science.
Experts And Viewpoints, May 2018
The Case Against Thrombolytic Therapy in Stroke A New York Times article siding with neurologists in their debate with emergency medicine over the benefits of tPA in ischemic stroke prompted Dr Mandrola to take a closer look at the data.
Experts And Viewpoints, April 2018
Pharmacists and Barbers on the Cutting Edge of Medicine Dr Mandrola's hands-down favorite study from the 2018 American College of Cardiology meeting showed that a pharmacist-led intervention in black-owned barbershops cut hypertension in black men.
Experts And Viewpoints, March 2018
ACC 2018 Ten Quick Thoughts on ODYSSEY Despite a suggested mortality benefit for the PCSK9 inhibitor alirocumab, in high-risk ACS patients, a return to lipid targets may be the cost-effective lesson from this trial, argues Dr Mandrola.
Experts And Viewpoints, March 2018
ACC 2018 The VEST Trial Failed, and So Did the Press Release The first randomized trial on the wearable cardioverter defibrillator didn't meet its primary endpoint, yet the press release was overly positive.
Experts And Viewpoints, March 2018
Mandrola Previews 2018 ACC PCSK9 inhibitors, LifeVest, and his-bundle pacing are among Dr Mandrola's picks for what to look for at the 2018 American College of Cardiology Scientific Sessions.
Experts And Viewpoints, March 2018
Donald Trump Has Coronary Calcium: Is That Helpful to Know? A briefing on the President's health included the detail that he has a coronary artery calcium score of 133. Dr Mandrola questions whether Trump should have even had a calcium scan.
Experts And Viewpoints, February 2018
Nine Things to Remember About CASTLE-AF Ablation of atrial fibrillation in patients with heart failure lowered all-cause mortality in this trial, but Dr Mandrola urges electrophysiologists not to overextrapolate these impressive results.
Experts And Viewpoints, February 2018
Flawed Surgical Left Atrial Appendage Closure Study Oversold An observational study on surgical left atrial appendage closure prompts Dr Mandrola to bemoan the overreach of the authors and editorialist.
Experts And Viewpoints, January 2018
Mandrola's Top 10 Cardiology Stories of 2017 Controversy surrounding saturated fat and sham PCI make this year's list as well as a few medical reversals and the continuing opioid crisis. What topics would you add or omit?
Experts And Viewpoints, December 2017
Overdiagnosis Only a Matter of Time With ECG Watches An Apple Watch with an ECG reader may be fun for specific tasks, but it's fantasy to think it will improve health outcomes, according to this electrophysiologist.
Experts And Viewpoints, December 2017
AHA Better Patient Decisions: A Destination Within Reach A study showing that a comprehensive decision aid could help patients make treatment choices in line with their values is Dr Mandrola’s favorite trial of AHA 2017.
Experts And Viewpoints, November 2017
AHA What if Quality Measures Increased Mortality? Dr Mandrola reports on a provocative study showing that reducing readmissions for heart failure associates with higher mortality.
Experts And Viewpoints, November 2017
AHA Ushering in a New Era of Disease Prediction Dr Mandrola attended a young investigators award session and reports on the future of risk prediction--which means knowing our DNA.
Experts And Viewpoints, November 2017
TCT Seven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
Experts And Viewpoints, November 2017
AHA Mandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
Experts And Viewpoints, November 2017
Coronary Stents Humbled Yet Again in Stable CAD ORBITA, a sham-control PCI trial, found no angina benefit for stents in patients with stable CAD. Ten years after COURAGE, it's high time cardiologists treat patients, not lesions, pleads Dr Mandrola.
Experts And Viewpoints, November 2017

Trials and Fibrillations with Dr John Mandrola

About

Membership

Apps

WebMD Network

Editions

Trials and Fibrillations with Dr John Mandrola

Find Us On

About

Membership

Apps

WebMD Network

Editions